A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Conditions: Overactive Bladder Interventions: Drug: Mirabegron 50 MG; Drug: Oxybutynin Chloride 5 MG Sponsors: Seoul National University Hospital; Il-Yang Pharm Not yet recruiting

https://clinicaltrials.gov/study/NCT06181591

Source: ClinicalTrials.gov - December 25, 2023 Category: Research Source Type: clinical trials